FDA clears Johnson & Johnson’s Icotyde for plaque psoriasis
Johnson & Johnson has scored a notable FDA win in dermatology with the March 18, 2026 approval of Icotyde (icotrokinra) for moderate-to-severe plaque psoriasis in adults and pediatric patients 12 years and older weighing at least 40 kg who are candidates for systemic therapy or phototherapy. The drug is approved as a once-daily oral tablet and, according to J&J, is the first and only oral peptide targeting the IL-23 receptor to reach the U.S. market. (investor.jnj.com)
The approval has been building for some time. Icotrokinra, previously known as JNJ-2113 and earlier PN-235, emerged from a partnership in which Protagonist Therapeutics handled early development and J&J took on later-stage development and commercialization. J&J disclosed its U.S. filing in 2025, framing the product as a potential shift in the psoriasis treatment paradigm, especially for patients and prescribers looking for an oral alternative to injectable biologics. (irp.cdn-website.com)
What appears to have helped the product stand out is the breadth of its late-stage package. Protagonist said the FDA approval was supported by four Phase 3 studies that met all primary endpoints and showed a favorable safety profile across roughly 2,500 patients. Earlier J&J readouts from the ICONIC-LEAD study showed strong placebo-separated responses, and in 2025 the company reported that ICONIC-ADVANCE 1 and 2 demonstrated superiority over deucravacitinib on skin-clearance measures, with adverse event rates described as similar to placebo and numerically lower than deucravacitinib through week 24. (irp.cdn-website.com)
J&J and affiliated experts are already trying to define where the drug fits in practice. In the approval announcement, dermatologist Linda Stein Gold, MD, said the combination of skin clearance, safety profile, and once-daily oral dosing could make the drug easier to integrate into routine care, particularly as treatment guidance evolves on when to move beyond topical cycling. That framing matters because psoriasis prescribing has increasingly centered on balancing efficacy, convenience, safety monitoring, and patient preference, not just raw response rates. (investor.jnj.com)
The competitive backdrop is also getting more crowded. Takeda reported late-breaking AAD 2026 Phase 3 data for zasocitinib, another once-daily oral therapy for moderate-to-severe plaque psoriasis, and said it plans to move toward regulatory submission starting in fiscal 2026. In the company’s release, treatment-emergent adverse events through week 16 were 62.1% for zasocitinib, versus 46.9% for placebo and 50.5% for apremilast, with upper respiratory tract infection, nasopharyngitis, and acne among the most common adverse events. While cross-trial comparisons have obvious limits, the broader takeaway is clear: oral systemic psoriasis therapy is entering a more competitive phase, and Icotyde’s first-mover advantage may be important. (takeda.com)
Why it matters: For healthcare professionals, Icotyde’s approval is less about a single new brand and more about a potential shift in treatment sequencing. An oral IL-23 pathway therapy could appeal to patients who want systemic efficacy without injections, and the adolescent-inclusive label broadens the eligible population. The key questions now are practical ones: how payers cover it relative to established biologics and oral competitors, whether real-world adherence matches the convenience promise, and how prescribers interpret safety and durability as more post-approval data emerge. None of that is veterinary-specific, but it is the kind of regulatory and market movement clinicians across medicine watch closely because it shapes formulary behavior, specialty pharmacy workflows, and patient expectations around oral targeted therapies. (investor.jnj.com)
What to watch: Near term, watch for U.S. launch details, payer coverage, and publication of fuller label and real-world use information. Also watch the competitive timeline: J&J is continuing to release longer-term icotrokinra data, while Takeda is advancing zasocitinib toward submission, setting up a likely contest over efficacy, convenience, and safety positioning in oral psoriasis care over the next 12 to 18 months. (investor.jnj.com)